News about Global Pharma

Mabtech, Sai Life Sciences Partner to Expand Advanced Immunology Services in the U.S.

Mabtech, Sai Life Sciences Partner to Expand Advanced Immunology Services in the U.S.

Mabtech and Sai Life Sciences collaborate to deploy EYRA multiplex platform in Boston, enhancing access to advanced immune profiling for biopharma and biotech research.

Global Pharma | 19/03/2026 | By News Bureau 222

FTC Tracks Pharma Strategies as Patent Cliff Approaches

FTC Tracks Pharma Strategies as Patent Cliff Approaches

The US Federal Trade Commission (FTC) is keeping a close watch on how pharmaceutical companies respond as several blockbuster drugs approach the end of their patent life. The regulator is particularly concerned about practices that could delay the entry of lower-cost generic medicines.

Global Pharma | 18/03/2026 | By Darshana 169

Roche Boosts AI Muscle with Nvidia Chip Expansion to Accelerate Drug Discovery

Roche Boosts AI Muscle with Nvidia Chip Expansion to Accelerate Drug Discovery

Swiss pharma major Roche has significantly expanded its artificial intelligence (AI) capabilities by deploying thousands of advanced GPUs from Nvidia, marking one of the largest AI infrastructure investments in the pharmaceutical sector.

Global Pharma | 17/03/2026 | By Darshana 160

Zuellig Pharma Acquires Rights to Cialis from Eli Lilly and Company in Hong Kong, Macau and South Korea

Zuellig Pharma Acquires Rights to Cialis from Eli Lilly and Company in Hong Kong, Macau and South Korea

Zuellig Pharma has acquired rights to Cialis from Eli Lilly and Company in Hong Kong, Macau and South Korea, expanding its ownership of the men’s health drug across 11 Asian markets.

Global Pharma | 16/03/2026 | By News Bureau 445

Epilepsy Foundation of America Partners with SeizeSense to Launch Nationwide Seizure Safety Awareness Campaign in AMC Theatres

Epilepsy Foundation of America Partners with SeizeSense to Launch Nationwide Seizure Safety Awareness Campaign in AMC Theatres

Epilepsy Foundation of America and youth-led nonprofit SeizeSense launch a national PSA campaign in US cinemas to educate audiences on seizure recognition and first aid.

Global Pharma | 10/03/2026 | By News Bureau 145

Sanofi Board Nominates Christel Heydemann as Independent Director

Sanofi Board Nominates Christel Heydemann as Independent Director

Sanofi has nominated Christel Heydemann as an Independent Director, subject to shareholder approval at its AGM on 29 April. The company also announced that Patrick Kron, Independent Director and Chairman of the Nomination, Governance and CSR Committee, will step down at the end of his term.

Global Pharma | 07/03/2026 | By News Bureau 313

UK Space Agency Launches Initiative to Accelerate Development of Space-Manufactured Medicines

UK Space Agency Launches Initiative to Accelerate Development of Space-Manufactured Medicines

UK Space Agency, with Medicines and Healthcare products Regulatory Agency and partners, unveils regulatory support and innovation programmes to help companies develop microgravity-manufactured medicines and bring them from orbit to patients.

Global Pharma | 07/03/2026 | By News Bureau 185

IceCure Medical Study in PLOS One Highlights ProSense Cryoablation for Benign Breast Tumours

IceCure Medical Study in PLOS One Highlights ProSense Cryoablation for Benign Breast Tumours

Independent Hungarian study shows ProSense cryoablation achieves up to 92.9 percent tumour reduction in fibroadenomas, supporting minimally invasive alternatives to surgery for benign breast lesions.

Global Pharma | 03/03/2026 | By News Bureau 134

IDEAYA Biosciences Enrols First Patient in Phase I Trial of IDE034 Bispecific TOP1 ADC

IDEAYA Biosciences Enrols First Patient in Phase I Trial of IDE034 Bispecific TOP1 ADC

Precision oncology firm IDEAYA begins Phase I evaluation of IDE034, a PTK7/B7H3 bispecific TOP1 ADC, advancing its ADC and DNA damage response combination strategy in solid tumours.

Global Pharma | 02/03/2026 | By News Bureau 254

China Approves Jaypirca for Relapsed CLL and SLL Patients

China Approves Jaypirca for Relapsed CLL and SLL Patients

Jaypirca (pirtobrutinib) by Innovent Biologics has been approved in China for the treatment of adults with relapsed or refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL). The BTK inhibitor is designed to overcome resistance associated with prior covalent BTK therapies.

Global Pharma | 02/03/2026 | By News Bureau 173

 
 

 

 

We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.

More information: Privacy Policy

 pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members